OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Langer on the Need for Reflex Testing in NSCLC

November 10th 2021

Corey J. Langer, MD, discusses the need for reflex testing in patients with non–small cell lung cancer.

Dr. Hanna on the Efficacy of Tipifarnib in HRAS-Mutated Head and Neck Cancer

November 10th 2021

Glenn J. Hanna, MD, discusses promising data reported with tipifarnib in patients with HRAS-mutated head and neck cancer.

Dr. Lazar on Risk Stratification for Chemotherapy and Adjuvant Therapy in Lung Cancer

November 10th 2021

John F. Lazar, MD, discusses risk stratification for chemotherapy and adjuvant therapy in lung cancer.

Dr. Bordoni on the Utility of Adjuvant Osimertinib in ​EGFR-Mutant Lung Cancer

November 10th 2021

Rodolfo Bordoni, MD, discusses the utility of ​adjuvant osimertinib in lung cancer.

Dr. Saif on the Rationale to Utilize PARP Inhibitors in BRCA+ Pancreatic Cancer

November 10th 2021

Wasif M. Saif, MD, MBBS, discusses the rationale to utilize PARP inhibitors in BRCA-mutated pancreatic cancer.

Dr. Parker Discusses the Importance of Optimizing Treatment in Multiple Myeloma

November 10th 2021

Terri Parker, MD, discusses considerations to optimize treatment in multiple myeloma.

Dr. Kimmick on the Results of the ATEMPT Trial in Early-Stage HER2+ Breast Cancer

November 9th 2021

Gretchen G. Kimmick, MD, MS, discusses the results of the phase 2 ATEMPT trial in early-stage HER2-positive breast cancer

Dr. Stephens Discusses Optimizing Treatment Selection in CLL

November 9th 2021

Deborah M. Stephens, DO, director of the CLL and Lymphoma Program, Huntsman Cancer Institute, discusses optimizing treatment selection in chronic lymphocytic leukemia.

Dr. Mukherjee on Determining When to Initiate Immunotherapy in Gastroesophageal Cancer

November 9th 2021

Sarbajit Mukherjee, MD, MS, discusses considerations to inform when to initiate immunotherapy in gastroesophageal cancer.

Dr. Sammons on the Clinical Implications of DESTINY-Breast03 in HER2+ Breast Cancer

November 9th 2021

Sarah Sammons, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Dr. Marshall on the Potential Utility of Trastuzumab Deruxtecan in HER2+ Gastric Cancer

November 8th 2021

John L. Marshall, MD, discusses the potential utility of trastuzumab deruxtecan in HER2-positive gastric cancer.

Dr. Mato on the Potential for Early Utilization of CAR T-Cell Therapy in CLL

November 8th 2021

Anthony Mato, MD, MSCE, discusses the potential utilization of CAR T-cell therapy in earlier lines of therapy in chronic lymphocytic leukemia.

Dr. Esteva on the Impact of Subcutaneous Pertuzumab/Trastuzumab in HER2+ Breast Cancer

November 8th 2021

Francisco Javier Esteva, MD, PhD, discusses the clinical implications of the fixed-dose regimen comprised of subcutaneous trastuzumab and pertuzumab in the treatment of patients with HER2-positive breast cancer.

Dr. Siddiqui on the Potential for Novel Imaging Techniques in Nonmetastatic CRPC

November 8th 2021

Bilal A. Siddiqui, MD, discusses the potential for novel imaging in patients with nonmetastatic castration-resistant prostate cancer.

Dr. Saxena on a Challenging Case of NSCLC

November 8th 2021

Ashish Saxena, MD, PhD, discusses a challenging case of a patient with non–small cell lung cancer.

Dr. Zauderer on the Importance of Optimizing Care in Mesothelioma

November 8th 2021

Marjorie G. Zauderer, MD, discusses the importance of optimizing care for patients with mesothelioma.

Dr. Brahmer on the Utility of Consolidative Immunotherapy Vs Targeted Therapy in NSCLC

November 6th 2021

Julie Renee Brahmer, MD, MSc, discusses questions regarding the role of consolidative immunotherapy vs targeted therapy in locally advanced non–small cell lung cancer.

Dr. Kris on Next Steps to Improve Outcomes in Lung Cancer

November 6th 2021

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the next steps to improve outcomes for patients with lung cancer.

Dr. Ivanick on Advances in Interventional Pulmonology

November 5th 2021

Nathaniel Ivanick, MD, FCCP, discusses advancements in interventional pulmonology.

Dr. Seetharamu on Utilizing a Patient-Centered Treatment Approach in Lung Cancer

November 5th 2021

Nagashree Seetharamu, MD, MBBS, discusses the importance of utilizing a patient-centered treatment approach in lung cancer.

NEXT PAGE
PREVIOUS PAGE